The site, to be known as Amgen, will be located in HITEC City, a suburb of Hyderabad, occupying six floors of the RMZ Spire Tower, with a potential to accommodate up to 3,000 people. The site will be operational in Q4 2024.
Amgen India will initially build and accelerate new technology solutions and digital capabilities at scale that will enhance efficiencies across the enterprise.
The site will offer roles that strengthen key areas of Amgen’s business, including artificial intelligence (AI), data science, life science and other additional global capabilities over time.
Som Chattopadhyay has been appointed as national executive to lead Amgen’s expanded presence in India.
The California based Amgen with revenues of $28.2 billion in 2023, is one of the world’s leading biotech companies with nearly 27,000 employees and has a presence in around 100 countries and regions worldwide, including India.”At a time when a quickly aging global population needs more innovation, the convergence of biotechnology and technology is enabling Amgen to work with greater speed, confidence, and efficiency — an incredibly exciting milestone for which we have been preparing for over a decade,” said David M. Reese, executive vice president and chief technology officer at Amgen.”Amgen has been a leader in biotechnology for over 40 years and establishing this new site in India, a country known for its world-class technology and life sciences talent, marks a significant step forward in our journey to deliver on our mission to serve patients,” Reese added.
“Amgen’s new site in Hyderabad underscores the city’s position as a hub for innovation and technology,” Chief Minister Anumula Revanth Reddy said welcoming the investment.
Multinational pharma and medtech companies are setting up GCCs in India to take advantage of talent, especially in the technology domain to support their global operations as well as building AI tools to optimise manufacturing operations, finding drug discovery targets, simulating clinical trials among others.
In recent months Sanofi has announced investment of Rs 3600 crore on expansion of its GCC in Hyderabad, British-Swedish drugmaker AstraZeneca said it plans to invest Rs 250 crore to grow its Global Innovation and Technology Centre in Chennai, bringing some 1,300 highly skilled roles by 2025.
Novartis was an early entrant to India, the Swiss pharma company employs more than 8,100 associates in India, of which lion share work at its GCC in Hyderabad.
Bristol Myers Squibb (BMS), Bayer, Merck, Novo Nordisk, Medtronic, Siemens Healthineers, GE Healthcare, among others have established GCCs in India.
